Beilu Pharma's Iohexol Injection Won the Bid in the Fifth round of National Centralized Drug Procurement

2021/06/24

On June 23, Beilu Pharma participated in the fifth round of national centralized drug procurement organized by the National Organization for Centralized Drug Procurement and Use of the Joint Procurement Office.

The company's Iohexol injection (100ml: 35g(I)) was proposed to be selected in the centralized procurement.

Iohexol Injection (100ml: 35g(I)) passed the consistency evaluation of generic products’ quality and efficacy in Apr. 2021. In 2020, the sales revenue from Iohexol Injection was RMB220.96 million, accounting for approximately 26.71% of the operation income of the company.

The relevant information is hereby announced as below:

Generic name of the drug	Specification	Indication	Proposed selected price	Procurement lead time
Iohexol Injection	100ml:35g(I)	X-ray contrast agents It can be used for cardiovascular angiography, arteriography, urography, venography, enhanced CT examinations etc.	N/A	2 years

Note: The abovementioned product’s proposed winning price and information will be subject to the final announcement issued by the Joint Procurement Office. You can have a look at the iohexol package insert here.

Iohexol Injection

Related News

Beilu Pharma Established a Wholly-owned R&D Subsidiary
September 7, 2022Taking the "Top 100 Chinese Pharmaceutical Enterprises" as the medium and long-term goal, Beilu Pharma has decided to choose not only the Contrast Agent field, Central Nervous System (Propri...view
To Understand the Development of Iodinated Contrast Agents
May 13, 2021For the purpose of medical imaging, a certain substance is introduced into the human body to change the image contrast of the body's local tissues.view
Beilu Pharmaceutical has been awarded "Beijing Advanced Unit of Adverse Drug Reactions Daily Monitoring" for 4 consecutive years.
August 4, 2022Recently, the Beijing Municipal Drug Administration and Beijing Municipal Health Commission issued the "notice on the outstanding Performance of units and individuals in the monitoring of adverse...view
New Specifications of Repaglinide Tablets from Beilu Pharma Were Deemed to Have Passed the Generic Drugs Quality and Efficacy Consistency Evaluation
December 20, 2021Now, our company received the Notification of Approval of Supplementary Application for Repaglinide Tablets issued by the State Medical Products Administration (Notification No. : 2021 B04618). After ...view
Beilu Pharma's Subsidiary, Hichi Pharmaceutical, Obtains Korean Registration for Iohexol.
September 21, 2023Beilu Pharmaceutical's subsidiary, Zhejiang Hichi Pharmaceutical, has recently obtained the certificate of registration for Iohexol API from the Ministry of Food and Drug Safety in Korea.This regi...view
Beilu Pharmaceutical's Gadobenate Dimeglumine Injection Passes Generic Drug Consistency Evaluation!
March 22, 2024Recently, Beilu Pharmaceutical received the "Drug Supplementary Application Approval Notice" (Notice Number: 2024B01144) for Gadobenate Dimeglumine Injection issued by the National Medical P...view

Beilu Pharma's Iohexol Injection Won the Bid in the Fifth round of National Centralized Drug Procurement

Beilu Pharma Established a Wholly-owned R&D Subsidiary

To Understand the Development of Iodinated Contrast Agents

Beilu Pharmaceutical has been awarded "Beijing Advanced Unit of Adverse Drug Reactions Daily Monitoring" for 4 consecutive years.

New Specifications of Repaglinide Tablets from Beilu Pharma Were Deemed to Have Passed the Generic Drugs Quality and Efficacy Consistency Evaluation

Beilu Pharma's Subsidiary, Hichi Pharmaceutical, Obtains Korean Registration for Iohexol.

Beilu Pharmaceutical's Gadobenate Dimeglumine Injection Passes Generic Drug Consistency Evaluation!